Matinas BioPharma Holdings

MTNB69

Penny Stock

$3.52arrow_drop_down2.00%-$0.07

Penny Stock

MTNB69

$3.52

arrow_drop_down2.00%-$0.07

Penny Stock

Performance History

Key Stats
Open	$3.55
Prev. Close	$3.59
EPS	-5.50
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$18.01M
PE Ratio	-

	LOW	HIGH
Day Range	3.52	3.64
52 Week Range	3.28	44.50

Ratios







EPS	-5.50

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Matinas BioPharma Holdings (MTNB)

Matinas BioPharma Holdings Inc (MTNB) is a biopharmaceutical company that focuses on developing innovative therapeutics based on its lipid nano-crystal (LNC) drug delivery platform. The company aims to address unmet medical needs in the areas of fungal and bacterial infections, as well as non-alcoholic steatohepatitis (NASH), a liver disease. MTNB's LNC platform enables the effective delivery of drugs with improved bioavailability, solubility, and stability.

MTNB stock has a volatile price history, with fluctuations driven by various factors including clinical trial results, regulatory news, and market sentiment. Investors should carefully consider the risks associated with investing in biopharmaceutical companies, as the industry is highly competitive and subject to regulatory challenges. Past performance is not indicative of future results.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Jerome D. Jabbour J.D.
Headquarters: Bedminster
Employees: 34
Exchange: NYSE

add Matinas BioPharma Holdings to watchlist

Keep an eye on Matinas BioPharma Holdings

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Matinas BioPharma Holdings (MTNB) stock price performance year to date (YTD)?

As of the latest data, Matinas BioPharma Holdings (MTNB) has a year-to-date price change of -68.71%. Over the past month, the stock has experienced a price change of -44.13%. Over the last three months, the change has been -55.78%. Over the past six months, the figure is -74.17%. Looking at a longer horizon, the five-year price change stands at -89.06%.

help

What is Matinas BioPharma Holdings 's (MTNB) price per share?

The current price per share for Matinas BioPharma Holdings (MTNB) is $3.52. The stock has seen a price change of -$0.07 recently, indicating a -2% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Matinas BioPharma Holdings (MTNB)?

For Matinas BioPharma Holdings (MTNB), the 52-week high is $44.5, which is 1.16K% from the current price. The 52-week low is $3.28, the current price is 7.32% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Matinas BioPharma Holdings (MTNB) a growth stock?

Matinas BioPharma Holdings (MTNB) has shown an average price growth of 0.41% over the past three years. It has received a score of 16 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Matinas BioPharma Holdings as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

Is Matinas BioPharma Holdings (MTNB) a profitable company?

Matinas BioPharma Holdings (MTNB) has a net income of -$22.94M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 14.14% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.1M, although specific revenue growth data is currently not available. The gross profit is $155K. Operating income is noted at -$23.77M. Furthermore, the EBITDA is -$23.38M.

help

What is the market capitalization of Matinas BioPharma Holdings (MTNB)?

Matinas BioPharma Holdings (MTNB) has a market capitalization of $18.02M. The average daily trading volume is 40.94K, indicating the stock's liquidity and investor engagement.

News

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

HEALTH

CLINICAL STUDY

6/24/2024

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program